AnorMED To Commence Trading On AMEX

VANCOUVER, Nov. 3 /PRNewswire-FirstCall/ - AnorMED Inc. (the “Company” or “AnorMED”) is pleased to announce that the United States Securities & Exchange Commission has declared the Company’s registration statement on Form 40-F effective on November 3, 2005. In addition, AnorMED has received approval for the listing of its common shares on the American Stock Exchange (the “AMEX”). AnorMED’s shares will begin trading on the AMEX on November 4, 2005 under the stock symbol AOM.

“We believe that the listing of AnorMED’s common shares on the AMEX is a positive step towards increasing our presence internationally by allowing investors to trade our shares on a major U.S. exchange,” commented Dr. Michael Abrams, CEO and President of AnorMED Inc.

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. Information on AnorMED is available on the Company’s website: www.anormed.com.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update any forward-looking statements as conditions change. Investors are referred to the discussion of the risks factors associated with the Company’s business contained in the Company’s Annual Information Form filed with securities regulatory authorities dated June 23, 2005.

For further information: Kim Nelson, Ph.D. W.J. (Bill) Adams, C.A., Manager, Investor Relations Chief Financial Officer Tel: 604-532-4654 Tel: 604-530-1057 Cell: 604-614-2886 Email: info@anormed.com Email: knelson@anormed.com

AnorMED Inc.

CONTACT: Kim Nelson, Ph.D., Manager, Investor Relations, Tel: (604)532-4654, Cell: (604) 614-2886, Email: knelson@anormed.com; W.J. (Bill)Adams, C.A., Chief Financial Officer, Tel: (604) 530-1057, Email:info@anormed.com